G.RE.T.A. Group for Reconstructive and Therapeutic Advancements, Milan, Naples, Catania, Italy.
Medical Statistics Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
Aesthetic Plast Surg. 2021 Dec;45(6):2593-2601. doi: 10.1007/s00266-021-02260-0. Epub 2021 Apr 9.
Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) is a distinctive type of T-cell lymphoma arising around breast implants. We performed a review of the existing literature with the aim of providing an evidence-based overview of the available data on BIA-ALCL with a standardized evaluation of the quality of the studies and investigating the potential association between textured breast implants and BIA-ALCL.We analyzed the literature reporting estimates of relative or absolute risks of BIA-ALCL in case-control, cohort studies and case series studies. The total number of BIA-ALCL cases reported in literature is very low. Furthermore, most of the reported cases have been reported in case-control studies or case series. This means that our knowledge is based on a low level of evidence. Moreover, low-medium quality scores were observed in the included case series studies. In relation to the rarity of the event, better information could only derived by international cooperation to pool together data deriving from all over the world, with the clear need of better reporting patients and implant characteristics in case series and when adding data to public registries. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)是一种独特的 T 细胞淋巴瘤,发生在乳房植入物周围。我们对现有文献进行了回顾,旨在提供关于 BIA-ALCL 的现有数据的循证概述,并对研究质量进行标准化评估,并探讨纹理乳房植入物与 BIA-ALCL 之间的潜在关联。我们分析了文献中报告的病例对照、队列研究和病例系列研究中 BIA-ALCL 的相对或绝对风险估计值。文献中报告的 BIA-ALCL 病例总数非常低。此外,大多数报告的病例均在病例对照研究或病例系列研究中报告。这意味着我们的知识基于低水平的证据。此外,纳入的病例系列研究的质量评分较低。考虑到事件的罕见性,只有通过国际合作才能更好地收集来自世界各地的数据,从而明确需要更好地报告病例和植入物特征,在病例系列研究中以及在向公共登记处添加数据时。证据水平 IV:本刊要求作者为每篇文章分配一个证据水平。有关这些循证医学评级的完整描述,请参阅目录或在线作者指南 www.springer.com/00266 。